Kenalog, tablets 4 mg, 50 pcs.

Kenalog is antipruritic, immunosuppressive, anti-allergic, anti-inflammatory.

Induces formation of lipocortins, inhibits the release of inflammatory mediators by eosinophils, reduces the number of mast cells that produce hyaluronic acid. Reduces capillary permeability, stabilizes cellular, including lysosomal membranes and membranes.

Inhibits the release of cytokines (interleukin 1, 2, gamma-interferon) from lymphocytes and macrophages. Increases gluconeogenesis, reduces tissue utilization of glucose and activates catabolic processes.

Indications

Rheumatism, rheumatoid arthritis, systemic lupus erythematosus and other collagenoses, acute allergic reactions, allergic skin diseases, severe bronchial asthma, erythema multiforme, hemorrhagic diathesis, hemolytic anemia, lymphoma, leukemia.

Active ingredient

Composition

1 tablet contains:

Active substances:

triamcinolone acetonide 40 mg.

How to take, the dosage

In adults, 4-20 mg per day in 2-3 doses.

After improvement of the condition, the daily dose is gradually reduced by 1-2 mg every 2-3 days to a minimum maintenance dose of 1 mg and complete withdrawal of therapy.

Interaction

Concomitant use with anabolic steroids, androgens increases the risk of peripheral edema, acne.

In concomitant use with antithyroid drugs and thyroid hormones may change thyroid function.

Concomitant use with histamine H1-receptor blockers decreases the effect of triamcinolone; with hormonal contraceptives – potentiates the effect of triamcinolone.

Hypocalcemia associated with the use of triamcinolone may lead to an increase in the duration of neuromuscular blockade caused by the action of depolarizing myorelaxants when they are used simultaneously.

Concomitant use with immunosuppressants increases the risk of bacterial and viral infections.

Concomitant use with potassium-saving diuretics may cause hypokalemia.

Concomitant use may decrease the effectiveness of indirect anticoagulants, heparin, streptokinase, urokinase, increased risk of erosive ulcerative lesions and gastrointestinal bleeding.

Concomitant use with NSAIDs (including acetylsalicylic acid) increases the risk of erosive ulcerative lesions and bleeding from the gastrointestinal tract.

When concomitant use weaken the effect of oral hypoglycemic agents and insulin; with laxatives – possible hypokalemia; with cardiac glycosides – increased risk of cardiac arrhythmias and other toxic effects of glycosides.

Concomitant use with tricyclic antidepressants may increase psychiatric disorders associated with taking triamcinolone.

Concomitant use with m-cholinoblockers (including atropine) may increase intraocular pressure.

Concomitant use with amphotericin B, carbohydrate inhibitors leads to the risk of hypokalemia, left ventricular myocardial hypertrophy and circulatory failure.

Concomitant use with isoniazid may decrease the plasma concentration of isoniazid, mainly in persons with rapid acetylation.

Concomitant use may accelerate biotransformation and decrease plasma concentrations of mexiletine.

Concomitant use with paracetamol increases the risk of hypernatriemia, peripheral edema, increased calcium excretion, hypocalcemia, osteoporosis, hepatotoxicity of paracetamol.

In concomitant use with rifampicin, phenytoin, carbamazepine, barbiturates the metabolism of triamcinolone is accelerated due to induction of microsomal liver enzymes, its effect is reduced.

Concomitant use with ephedrine accelerates the metabolism of triamcinolone.

Special Instructions

It is not intended for intravenous administration.

With caution and under close medical supervision, use with edema syndrome, obesity, mental illness and gastrointestinal diseases. It is recommended that vitamin D and calcium-rich foods be taken during treatment.

After a single e/m administration at a dose of 60-100 mg for 24-48 hours, inhibition of adrenal function may be observed, which usually recovers after 30-40 days.

When used topically to prevent local infectious complications, it is recommended to use in combination with antimicrobials.

Parenteral use in children under 6 years of age is not recommended; 6-12 years of age if strictly indicated.

Long-term external use in children should be avoided regardless of age.

Contraindications

Side effects

Endocrine system disorders: redistribution of adipose tissue, menstrual disorders, increased blood glucose levels, inhibition of adrenal function, “moon-shaped face”, stretch marks, hirsutism, acne.

Metabolism disorders: edema, electrolyte imbalance, negative nitrogen balance, growth retardation in children.

Digestive system disorders: steroid gastric ulcer, gastrointestinal erosive ulcers, acute pancreatitis.

CNS disorders: seizures, sleep disorders, mental disorders, headaches and dizziness, weakness.

Muscular system disorders: myopathy, osteoporosis.

Cardiovascular system: arterial hypertension.

With regard to the blood coagulation system: thromboembolism.

An organ of vision: visual disturbances, posterior subcapsular cataract, increased intraocular pressure or exophthalmos, anaphylactic reactions.

Reactions due to immunosuppressive action: exacerbation of infectious diseases.

In intra-articular administration: joint pain, irritation at the injection site, depigmentation, sterile abscess, skin atrophy are possible; resorptive side effects are possible when administered in doses over 40 mg.

Inhalation use: headache, sneezing, coughing, dry mucous membranes of the mouth or nose, a feeling of irritation in the nose, hoarseness of the voice, rarely fungal infection of the nasopharynx caused by Candida albicans may occur.

In external use: itching, skin irritation, late reactions such as eczema, steroid acne, purpura are possible. Prolonged use of the ointment may cause secondary infectious lesions and atrophic skin changes.

Similarities